HER2 expression in breast cancer is critical for targeting, and the survival of HER2-positive patients have significantly improved with targeted antibodies. Traditional methods for analyzing HER2 expression in breast cancer are post-biopsy following immunohistochemistry and fluorescence in situ hybridization, which are characterized by invasiveness, incorrect presentation of HER2 expression in sampled specimens, and difficulty in sampling distant metastases. It is imperative to improve the expression analysis of HER2 in breast cancer, among which radio-labeled HER2 probes are a good choice. The HER2 affibody probe of breast cancer has been proved to have high affinity and imaging performance in clinical trials.

Cancer is one of the major diseases that seriously endanger human health. Cancer diagnosis and therapy are the main development fields of YuanBen. The pipelines under research include YB-01, YB-02, YB-03, YB-04 and YB-05.

With the aging of the world's population, neurodegenerative diseases bring heavy social burden to the society, families and individuals. The diagnosis of neurodegenerative diseases and anti-neurodegenerative drugs are important development fields of YuanBen, with YB-11, YB-12, YB-14 and YB-33 under research.

Diabetes leads to a sharp decline in the quality of life of patients. The development of new anti-diabetes drugs is the economic growth point of YuanBen, and the pipelines under research include YB-20 and YB-21.